Equities researchers at StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE - Get Free Report) in a research report issued on Saturday. The brokerage set a "sell" rating on the biotechnology company's stock.
Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald reiterated a "neutral" rating on shares of bluebird bio in a report on Monday, September 16th. Bank of America reduced their target price on bluebird bio from $4.00 to $3.00 and set a "buy" rating on the stock in a research report on Thursday, August 15th. JPMorgan Chase & Co. lowered bluebird bio from an "overweight" rating to a "neutral" rating in a report on Thursday, August 15th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $4.00 target price on shares of bluebird bio in a report on Thursday, August 15th. Finally, Wells Fargo & Company dropped their target price on bluebird bio from $3.00 to $2.00 and set an "equal weight" rating on the stock in a report on Wednesday, September 25th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, bluebird bio presently has an average rating of "Hold" and an average price target of $4.63.
Check Out Our Latest Research Report on BLUE
bluebird bio Stock Performance
Shares of bluebird bio stock opened at $0.47 on Friday. The stock's fifty day moving average is $0.53 and its two-hundred day moving average is $0.83. The company has a market capitalization of $90.36 million, a PE ratio of -0.21 and a beta of 0.75. The company has a quick ratio of 0.57, a current ratio of 0.68 and a debt-to-equity ratio of 0.37. bluebird bio has a 52 week low of $0.45 and a 52 week high of $5.53.
bluebird bio (NASDAQ:BLUE - Get Free Report) last announced its quarterly earnings data on Friday, September 13th. The biotechnology company reported ($0.36) EPS for the quarter. The business had revenue of $18.57 million during the quarter. bluebird bio had a negative net margin of 567.29% and a negative return on equity of 207.25%. As a group, analysts expect that bluebird bio will post -1.41 earnings per share for the current year.
Hedge Funds Weigh In On bluebird bio
Several hedge funds and other institutional investors have recently made changes to their positions in BLUE. Vanguard Group Inc. lifted its position in bluebird bio by 19.6% during the first quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company's stock worth $13,438,000 after buying an additional 1,723,081 shares in the last quarter. AQR Capital Management LLC lifted its position in bluebird bio by 315.3% during the second quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company's stock worth $1,223,000 after buying an additional 1,013,144 shares in the last quarter. Bank of New York Mellon Corp lifted its position in bluebird bio by 19.4% during the second quarter. Bank of New York Mellon Corp now owns 685,757 shares of the biotechnology company's stock worth $675,000 after buying an additional 111,574 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in bluebird bio by 38.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 325,111 shares of the biotechnology company's stock worth $416,000 after buying an additional 90,139 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in bluebird bio by 152.4% during the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company's stock worth $64,000 after buying an additional 74,185 shares in the last quarter. Hedge funds and other institutional investors own 87.43% of the company's stock.
About bluebird bio
(
Get Free Report)
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Featured Articles
Before you consider bluebird bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bluebird bio wasn't on the list.
While bluebird bio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
